We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
Read MoreHide Full Article
Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp reported second-quarter 2019 adjusted earnings per share (EPS) of $2.93, down 1.7% from the year-ago quarter. However, the bottom line edged past the Zacks Consensus Estimate by 1%.
On a reported basis, net earnings came in at $1.93 per share, declining 14.9% from the year-earlier figure.
Revenues in the quarter under review edged up 0.5% year over year to $2.88 billion. However, the top line lagged the Zacks Consensus Estimate of $2.90 billion.
Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise
This marginal year-over-year improvement was primarily led by 1.4% growth from acquisitions and organic growth of 1.7% (which includes the negative impact from Protecting Access to Medicare Act or PAMA of 0.9%), partially offset by a 1.9% negative impact from the disposition of businesses and an adverse foreign currency translation of approximately 0.7%.
Quarter Under Review
LabCorp reports under two operating segments: LabCorp Diagnostics and Covance Drug Development.
In the second quarter, LabCorp Diagnostics reported revenues of $1.76 billion, reflecting a 2.9% dip year over year. This downside was primarily due to a 2.8% headwind from the disposition of businesses and 0.3% lower organic revenues (including a 1.5% negative impact from the implementation of the PAMA). In addition, unfavorable foreign currency translation reduced revenues by approximately 0.2%. Growth from acquisitions was 0.4% in the quarter.
Excluding the disposition of businesses, the company reported a 0.9% slip in total volume (measured by requisition) and a 1% rise in revenue per requisition in the quarter under consideration.
Covance Drug Development’s revenues improved 6.8% to $1.13 billion in the second quarter. This upside was primarily attributed to 3.3% growth from acquisitions and organic growth of 5.5%, partially offset by the 1.6% adverse impact of foreign currency translation and a business disposition of 0.3%.
Gross margin contracted 51 bps to 28.6% in the reported quarter. Also, adjusted operating income was down 6.9% year over year to $410 million. Moreover, adjusted operating margin contracted 114 bps from the year-ago quarter to 14.2%.
LabCorp exited the second quarter with cash and cash equivalents of $265.4 million compared with $348.8 million at the end of the first quarter. Further, year to date, operating cash flow was $419.3 million, down from $567.1 million in the year-ago period. Additionally, free cash flow came in at $239.9 million in the period, down from $407.4 million a year ago.
In the quarter under discussion, the company returned $199.9 million to shareholders via share repurchases. LabCorp currently has $1.05 billion of authorization remaining under its existing share buyback plan.
Outlook
LabCorp has updated its 2019 guidance.
Revenue growth expectation has been tightened to the band of 1-2% from 2018 (earlier projected band was 0.5-2.5%). This includes a projected adverse impact from the disposition of businesses of around 1.5% and a negative foreign currency movement of roughly 0.5%. The Zacks Consensus Estimate for current-year revenues is pegged at $11.46 billion.
Adjusted EPS estimate for 2019 has been narrowed to a range of $11.10-$11.40 from the earlier band of $11.05-$11.45. The consensus mark of $11.28 for the metric is within this guided range.
Free cash flow is predicted from $950 million to $1.05 billion (unchanged).
Our Take
LabCorp exited the second quarter on a mixed note with earnings ahead of the Zacks Consensus Estimate but revenues lagging the mark. While increasing acquisitions and a favorable mix contributed to LabCorp’s Diagnostics business in the quarter, the disposition of certain businesses and the implementation of PAMA dented the company’s growth.
However, Covance Drug Development delivered year-over-year growth. Here too, the strength from acquisitions and organic growth were partially negated by the hostile impact of foreign currency translation.
Zacks Rank & Other Key Picks
LabCorp currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are Hologic Inc. (HOLX - Free Report) , DENTSPLY SIRONA Inc. (XRAY - Free Report) and Teleflex Inc. (TFX - Free Report) .
Hologic is scheduled to release second-quarter 2019 results on Jul 31. The Zacks Consensus Estimate for the quarter’s adjusted EPS is pegged at 61 cents and for revenues, stands at $834.6 million. The stock carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DENTSPLY SIRONA is scheduled to release second-quarter 2019 results on Aug 2. The Zacks Consensus Estimate for its adjusted EPS is pinned on 62 cents and for revenues, stands at $1.03 billion. The stock sports a Zacks Rank #1.
Teleflex is expected to release second-quarter 2019 results on Aug 1. The Zacks Consensus Estimate for its adjusted EPS is $2.59 and for its top line, $636.7 million. The stock has a Zacks Rank of 2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp reported second-quarter 2019 adjusted earnings per share (EPS) of $2.93, down 1.7% from the year-ago quarter. However, the bottom line edged past the Zacks Consensus Estimate by 1%.
On a reported basis, net earnings came in at $1.93 per share, declining 14.9% from the year-earlier figure.
Revenues in the quarter under review edged up 0.5% year over year to $2.88 billion. However, the top line lagged the Zacks Consensus Estimate of $2.90 billion.
Laboratory Corporation of America Holdings Price, Consensus and EPS Surprise
Laboratory Corporation of America Holdings price-consensus-eps-surprise-chart | Laboratory Corporation of America Holdings Quote
This marginal year-over-year improvement was primarily led by 1.4% growth from acquisitions and organic growth of 1.7% (which includes the negative impact from Protecting Access to Medicare Act or PAMA of 0.9%), partially offset by a 1.9% negative impact from the disposition of businesses and an adverse foreign currency translation of approximately 0.7%.
Quarter Under Review
LabCorp reports under two operating segments: LabCorp Diagnostics and Covance Drug Development.
In the second quarter, LabCorp Diagnostics reported revenues of $1.76 billion, reflecting a 2.9% dip year over year. This downside was primarily due to a 2.8% headwind from the disposition of businesses and 0.3% lower organic revenues (including a 1.5% negative impact from the implementation of the PAMA). In addition, unfavorable foreign currency translation reduced revenues by approximately 0.2%. Growth from acquisitions was 0.4% in the quarter.
Excluding the disposition of businesses, the company reported a 0.9% slip in total volume (measured by requisition) and a 1% rise in revenue per requisition in the quarter under consideration.
Covance Drug Development’s revenues improved 6.8% to $1.13 billion in the second quarter. This upside was primarily attributed to 3.3% growth from acquisitions and organic growth of 5.5%, partially offset by the 1.6% adverse impact of foreign currency translation and a business disposition of 0.3%.
Gross margin contracted 51 bps to 28.6% in the reported quarter. Also, adjusted operating income was down 6.9% year over year to $410 million. Moreover, adjusted operating margin contracted 114 bps from the year-ago quarter to 14.2%.
LabCorp exited the second quarter with cash and cash equivalents of $265.4 million compared with $348.8 million at the end of the first quarter. Further, year to date, operating cash flow was $419.3 million, down from $567.1 million in the year-ago period. Additionally, free cash flow came in at $239.9 million in the period, down from $407.4 million a year ago.
In the quarter under discussion, the company returned $199.9 million to shareholders via share repurchases. LabCorp currently has $1.05 billion of authorization remaining under its existing share buyback plan.
Outlook
LabCorp has updated its 2019 guidance.
Revenue growth expectation has been tightened to the band of 1-2% from 2018 (earlier projected band was 0.5-2.5%). This includes a projected adverse impact from the disposition of businesses of around 1.5% and a negative foreign currency movement of roughly 0.5%. The Zacks Consensus Estimate for current-year revenues is pegged at $11.46 billion.
Adjusted EPS estimate for 2019 has been narrowed to a range of $11.10-$11.40 from the earlier band of $11.05-$11.45. The consensus mark of $11.28 for the metric is within this guided range.
Free cash flow is predicted from $950 million to $1.05 billion (unchanged).
Our Take
LabCorp exited the second quarter on a mixed note with earnings ahead of the Zacks Consensus Estimate but revenues lagging the mark. While increasing acquisitions and a favorable mix contributed to LabCorp’s Diagnostics business in the quarter, the disposition of certain businesses and the implementation of PAMA dented the company’s growth.
However, Covance Drug Development delivered year-over-year growth. Here too, the strength from acquisitions and organic growth were partially negated by the hostile impact of foreign currency translation.
Zacks Rank & Other Key Picks
LabCorp currently carries a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are Hologic Inc. (HOLX - Free Report) , DENTSPLY SIRONA Inc. (XRAY - Free Report) and Teleflex Inc. (TFX - Free Report) .
Hologic is scheduled to release second-quarter 2019 results on Jul 31. The Zacks Consensus Estimate for the quarter’s adjusted EPS is pegged at 61 cents and for revenues, stands at $834.6 million. The stock carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DENTSPLY SIRONA is scheduled to release second-quarter 2019 results on Aug 2. The Zacks Consensus Estimate for its adjusted EPS is pinned on 62 cents and for revenues, stands at $1.03 billion. The stock sports a Zacks Rank #1.
Teleflex is expected to release second-quarter 2019 results on Aug 1. The Zacks Consensus Estimate for its adjusted EPS is $2.59 and for its top line, $636.7 million. The stock has a Zacks Rank of 2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>